The new application of the inPROBE biosensor in laparoscopic detection of gastric cancer

The company has announced in the past few hours the initiation of research aimed at determining the feasibility of assessing HER2 biomarker expression levels during diagnostic laparoscopy in patients with gastric cancer. The study was conducted in vitro using peritoneal lavage sample to demonstrate the presence of the HER2 biomarker with inPROBE^®.

In the peritoneal material collected during laparoscopy performed on patients with gastric cancer, the presence of the HER2 marker was demonstrated using both the ELISA test and the inPROBE^® technology platform. The results of this pilot study using the inPROBE^® probe indicate the potential application of this technology for the development of laparoscopic diagnostics with high sensitivity and specificity.

This groundbreaking discovery opens up the possibility for the Company to continue its work towards a new application of inPROBE^® technology—laparoscopic diagnostics for patients with gastric cancer.

"SDS Optic has been developing inPROBE from the very beginning not just as a single medical device but as a technological platform that can be scaled and applied in other areas of diagnostics and broad-spectrum molecular detection in vitro and in vivo. We have a strong team capable of exploring new application areas that are attractive not only from a scientific perspective but also for our shareholders. The support of the European Investment Bank has given us the comfort to explore the new potential of our technology,” says Marcin Staniszewski, CEO of SDS Optic.

According to the latest WHO reports, more than 660,000 patients worldwide lose the battle with stomach cancer each year. Annually, over 968,000 new cases are diagnosed, indicating a very low survival rate. Developing and implementing effective therapies, as well as methods for rapid and accurate diagnosis, has become a global priority. This is especially important since, similar to breast cancer, stomach cancer also exhibits so-called HER2-low levels, indicating low receptor overexpression, yet patients with this condition still respond to targeted therapy. This presents a significant challenge for the market, one that SDS Optic also aims to address.

The company informs that the obtained results are expected to directly contribute to the further development of the entire SDS Optic Capital Group, as well as to increase the scaling potential of the inPROBE^® technology platform. The company has also initiated the procedure for registering a new patent related to the conducted research. The company's CEO confirms that this groundbreaking discovery opens up the possibility for further work on a new application of the inPROBE^® technology—laparoscopic diagnostics for patients with gastric cancer.